Equities
Health CarePharmaceuticals & Biotechnology
  • Price (IDR)1,585.00
  • Today's Change-10.00 / -0.63%
  • Shares traded9.88m
  • 1 Year change17.41%
  • Beta1.0704
Data delayed at least 10 minutes, as of Apr 28 2017 09:05 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Apr 21, 2017, the consensus forecast amongst 16 polled investment analysts covering Kalbe Farma Tbk PT advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Apr 11, 2017. The previous consensus forecast advised investors to hold their position in Kalbe Farma Tbk PT.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy5
Outperform3
Hold6
Underperform2
Sell0

Share price forecast

The 15 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,750.00, with a high estimate of 2,200.00 and a low estimate of 1,350.00. The median estimate represents a 9.72% increase from the last price of 1,595.00.
High37.9%2,200.00
Med9.7%1,750.00
Low-15.4%1,350.00

Dividends

Historical dividend information is not available for Kalbe Farma Tbk PT.
Div growth (TTM)--
More ▼

Earnings history & estimates

On Mar 31, 2017, Kalbe Farma Tbk PT reported 4th quarter 2016 earnings of 12.74 per share. This result under-performed the 13.92 expectation of the one analyst following the company but exceeded last year's 4th quarter results by 18.38%.
The next earnings announcement is expected on Apr 27, 2017.
Average growth rate+8.36%
Kalbe Farma Tbk PT reported annual 2016 earnings of 49.06 per share on Mar 31, 2017.
Average growth rate+7.51%
More ▼

Revenue history & estimates

PT Kalbe Farma Tbk. had 4th quarter 2016 revenues of 5.00bn. This bettered the 4.99bn estimate of the one analyst covering the company. This was 5.01% above the prior year's 4th quarter results.
Average growth rate+1.40%
PT Kalbe Farma Tbk. had revenues for the full year 2016 of 19.37bn. This was 8.31% above the prior year's results.
Average growth rate+9.30%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.